The potential risk that glucagon might worsen glycemia is offset in the molecule by the powerful glucose-lowering, insulinotropic action of concurrent GLP-1 and GIP agonism
Severe renal impairment represents an important consideration
Phase 3 clinical trials of tirzepatide, source: reference [2] Semaglutide - OASIS 1 Since the introduction of Lilly's Tirzepatide, Novo Nordisk has been under pressure to move forward
Weeks 25-48: Weight loss typically slows as you approach a new equilibrium
Patients should seek medical attention if they experience severe or persistent gastrointestinal symptoms, signs of pancreatitis (severe abdominal pain radiating to the back), symptoms of thyroid tumors (neck mass, difficulty swallowing, persistent hoarseness), right upper quadrant pain, jaundice, reduced urine output, or unexplained hypoglycemia